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Methyl group and folate-dependent one-carbon metabolism play an integral role in 
health and disease. The donation of carbon in the production of nucleic acids from folate 
coenzymes and the methylation of biological compounds via transmethylation metabolism is 
important for maintenance of cells and tissues. Disruption of these tightly regulated 
pathways can result from numerous factors, including genetic polymorphisms of key 
enzymes, nutritional deficiencies, hormonal imbalances, or drug-nutrient interactions. 
Glycine N-methyltransferase (GNMT) is a key protein that regulates the supply of methyl 
groups for S-adenosylmethionine-dependent transmethylation reactions. We have shown that 
retinoid administration increases GNMT activity and protein abundance, thereby leading to 
the loss of methyl groups. Previous studies used pharmacological doses (30 ~.~mol/kg BW) of 
various retinoids administered daily for a total of 10 d. Here, we examined the dose- and 
time-dependent relationship between all-Mans-retinoic acid (ATRA) administration and 
induction of -GNMT, as well as determining additional indices of methyl group, 
homocysteine, and folate metabolism. For the dose-response study, rats were given either 0, 
1, 5, 10, 15 or 30 ~.~mol ATRA/kg BW for 10 d. For the time-course study, rats received 30 
µmol ATRAIkg BW for 0, 1, 2, 4, or 8 d. A significant increase (P = 0.009) in GNMT 
activity (105%) was observed with doses as low as 5 µmol/kg BW, whereas maximal 
induction (231 %) of GNMT activity was achieved at 30 µmol/kg BW. Induction of hepatic 
GNMT by ATRA was rapid, exhibiting a 31%increase following a single dose (1 d) and 
achieving maximal induction (95 %) after 4 d. Plasma methionine and homocysteine 
concentrations were decreased 42 and 5 3 %, respectively, in ATRA-treated rats compared to 
control values. In support of this finding, the hepatic activity of methionine synthase, the 
folate-dependent enzyme required for homocysteine remethylation, was elevated 40% in 
ATRA-treated rats. This work demonstrates that ATR.A administration exerts a rapid effect 
on hepatic methyl group, folate, and homocysteine metabolism at doses that are within the 
therapeutic range used by humans. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Complex pathways work efficiently in mammals unless affected by environmental 
factors or predisposed conditions. Perturbations from pharmaceuticals can disturb this 
otherwise finely tuned system and have a detrimental effect on overall health. Additionally, 
nutritional deficiencies and hormonal disturbances to metabolism can disturb a 
predetermined genetic condition, putting a person at risk for disease. Metabolic pathways are 
complex and the disruption in the performance of one pathway can have detrimental 
consequences in complementary pathways. For example, there are many aspects of folate-
dependent one-carbon metabolism that can be altered when its cycle is disturbed. The folate 
cycle donates carbon groups for the synthesis of purines and pyrimidines, the essential 
components of DNA. Therefore, disruption of folate metabolism can affect DNA synthesis 
and result in megaloblastic anemia. Many mechanisms are present to control the folate 
pathway, however disturbances to the interrelated methionine cycle can ultimately affect the 
synthesis of DNA. The methionine cycle, also known as methyl group metabolism, functions 
to donate methyl groups in the synthesis of essential compounds like neurotransmitters, 
phospholipids, creative, and regulate gene expression. A disturbance of these pathways by 
nutrient insufficiencies or environmental conditions can result in diseased states including 
cardiovascular disease and cancer. 
Vitamin A is afat-soluble vitamin that is important in growth and overall health in 
mammals. Vitamin A is involved in cell differentiation and is used pharmacologically to 
treat skin disorders such as acne and psoriasis, as well as the treatment of acute 
promyelocytic Leukemia. Although the therapeutic use of retinoids is beneficial, retinoids in 
high concentration are toxic and can produce damaging side effects; therefore patients are 
thoroughly examined for side effects before and during the course of treatment. 
Vitamin A and its derivatives have the ability to disrupt folate-dependent one-carbon 
and methyl group metabolism. Research has established a link between retinoids and the 
modulation of one-carbon metabolism. Recent studies have demonstrated that the most 
2 
biologically active retinoid, all-Mans-retinoic acid, has the ability to alter methyl. group 
metabolism by regulating important enzymes involved. High, pharmacological doses of all-
trans-retinoic acid administered for 7-1 ~ days have been shown to induce enzymes in methyl 
group metabolism. Currently there is no understanding of the dose-response relationship 
between this active vitamin A derivative and the enzymes it induces, nor the length of time 
required for induction in relationship to the mechanisms involved.- Modulation of folate-
dependent one-carbon and methyl- group metabolism can aid in comprehension of the cycle 
and its regulation as well as the impact it has on the body in times of impaired health. 
Thesis Organization 
This thesis contains an introductory chapter that gives an overview of research on 
folate-dependent one-carbon and methyl group metabolism and how disruptions to various 
aspects of the pathway can ultimately affect health. The second chapter contains a paper 
submitted to and accepted by the Journal of Nutrition that illustrates the dose-response and 
time-course behavior of all-trans-retinoic acid on the aforementioned pathways. Chapter 3 
gives closing thoughts and ideas for future research in this area. The appendices have 
supplemental data from the two studies in the second chapter and an additional study 
involving the impact of increased protein intake on folate-dependent one-carbon and methyl 
group metabolism. 
Literature Review 
Folate-dependent One-carbon and Methyl Group Metabolism 
Folate-dependent one-carbon and methyl group metabolism are Interrelated pathways 
that occur primarily in the liver and require a number of regulatory mechanisms to maintain 
function at an optimum level. This review describes the two pathways and their association 




Folate's role in the body is to distribute carbon for DNA synthesis and donate methyl 
groups for methyl group metabolism. Folate is introduced into the body by foods containing 
the water-soluble vitamin found most often in dark, green leafy vegetables. Folic acid, a 
monoglutamyl and oxidized form of folate, is another dietary source that is found in fortified 
foods and supplements (1). The importance of folate in health has increased the commercial 
availability of folic acid-fortified products, which typically dominates a person's daily intake. 
The Recommended Dietary Allowance (RDA) of folate is 400 dietary folate equivalents 
(DFE)/day (1 DFE = 1µg folate, 0.6 µg folic acid in fortified foods, or 0.5µg in 
supplements) for men and women and between 150 and 300 DFE/day for children, 
depending on the age. Folate plays an influential role in pregnancy and its requirement is 
600 DFE/day for pregnant women and 500 DFE/day for lactating women (2). Neural tube 
defects (NTDs) occur in the fetus and take place in 1 out of 1000 births in the United States 
and 1/3 of these are lost or terminated. There is a correlation between NTDs and folic acid 
but the mechanism of action is still unknown; however, it is strongly recommended for all 
women of childbearing age who are able to have children to consume 400 DFE/day (3). The 
malabsorption of folate has been associated with NTDs and may correlate to a higher rate of 
NTDs in some women (4). 
Severe folate deficiency can result in megaloblastic anemia, a disorder characterized 
by the formation of large, nucleated cells erythrocyte precursors. The reduction in DNA 
synthesis prevents these cells from dividing properly to become mature red blood cells (5). 
Other disorders from folate deficiency that can occur are leukopenia (decreased number of 
white blood cells) and thrombocytosis (surplus of platelets) (6). DNA methylation may 
ultimately affect cancer in the body as Lucock et al. (7) points out that improved folate status 
may prevent the formation of cervical and colon cancer as well as bronchial malignancies. 
These are prime examples of the impact folate have on human health. Other detrimental 
effects can occur from a folate deficiency but these will be discussed in detail later in 
relationship to methyl group metabolism. 
Folic acid is absorbed in the jejunum of the small intestine by hydrolysis with a 
conjugase intestinal enzyme located in the brush border (8). It is absorbed by both passive 
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diffusion and sodium-coupled carrier-mediated active transport before it is bound to folate-
binding proteins that transform folic acid to tetrahydrofolate (THF) and transport the newly 
formed molecules in plasma to the liver where half of the folate pool is located; THE is 
converted primarily to 5-methyl-THF and 10-formyl-THF in the liver before being 
transported to peripheral tissues (8). THE can be converted to be able to donate carbons in 
the production of purines and pyrimidines (Figure 1.1). The addition of formate to THE via 
the enzyme 10-formyl-THF synthase creates 10-formyl-THF, which donates carbon twice 
during purine biosynthesis, providing the G2 and C-8 in adenine and guanine as shown in 
Figure 1.2. A methyl group from serine transfers to THE via serine 
hydroxymefhyltransferase with cofactor vitamin B6 (in the form of PLP) and creates 5,10-
methylene-THF and the by-product glycine. The activity of the enzyme thymidylate 
synthase donates the auxiliary methylene group from 5,10-methylene-THF to produce 
deoxythymidylate monophosphate, the precursor of thymine (6,9) (Figure 1.1, 1.2). 
Dihydrofolate (DHF) is produced from this reaction and is reduced back to THE via DHF 
reductase. 
The folate derivative 5,10-methylene-THF can also be transformed by the enzyme 
5,10-methylene-THF reductase (MTHFR) and the cofactor Vitamin BZ (FADHZ) to 5-
methyl-THF, acoenzyme used in the remethylation of homocysteine to produce methionine 
de novo by methyl group metabolism (Figure 1.3) (10). Control of MTHFR is inhibited 
allosterically by S-adenosylmethionine (SAM), an important metabolite within the methyl 
group metabolism (11). SAM helps control the influx of methyl groups from the folate-
dependent one-carbon pool that are used for remethylation of homocysteine. If there is a 
sufficient amount of methionine to produce SAM, the increased SAM concentration inhibits 
the synthesis of 5-methyl-THF and the subsequent remethylation of homocysteine. There is 
more than one binding site for SAM on the MTHFR molecule and it will remain inactivated 
in the presence of SAM. The opposite action occurs if SAM levels decrease, producing an 
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Figure 1.1 Diagram of the conversion of ingested folic acid into its active form, 
tetrahydrofolate (THF). THF can either be metabolized to 10-formyl-THF or 5,10-
methylene-THF to donate carbons in the production of nucleic acids. 5,10-methylene-THF 
can also be metabolized via enzyme 5,10-methylene-THF-reductase (MTHFR) and cofactor 
B2 to produce 5-methyl-THF, which remethylates homocysteine in methyl group metabolism. 
Abbreviations: DHF, dihydrofolate; MTHFR, 5,10-methylenetetrahydrofolate reductase; 
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Figure 1.2 Conversion of tetralzydrofolate (THF) yields either 10-formyl-THF or 5,10-
methylene-THF. These two molecules donate carbons in the production of adenine, guanine, 
and thymine, the building blocks of DNA. 
In the remethylation of homocysteine to achieve basal methionine concentration, the 
transfer of the methyl group from 5-methyl-THF to homocysteine produces THF and 
methionine via methionine synthase (MS), which requires the cofactor Vitamin B 12 (also 
known as cobalamin}. The methyl group attaches to B12 and becomes 
methylcyanocobalamin, before being transferred to the homocysteine molecule (12). A 
deficiency of nutrients (i.e., B 12, folate) in combination with the irreversible action of 
MTHFR can cause the majority of folate to remain as ~-methyl-THF, creating a "methyl 
trap" that impairs folate-dependent reactions (13 ). A deficiency in B i 2 will decrease MS 
activity by as much as 80% and aid in the ``methyl trap" (13) along with unregulated MTHFR 
activity (14). Homocysteine can also be remethylated by betaine, a product of choline 
oxidation. This reaction is activated by the enzyme betaine:homocysteine methyltransferase 
(BHMT), an enzyme found only in the liver in all mammals while humans also possess 
BHMT in the kidney and lens (15). choline, B 12, methionine, and folic acid are collectively 















glutathione pyruvate taurine 
Figure 1.3 The enzyme methionine adenosyltransferase (MAT) activates S-
adenosylmethionine (SAM), which methylates numerous biological compounds. Glycine N-
methyltransferase (GNMT) is available to maintain the transmethylation potential. S-
adenosylhomocysteine (SAH) is produced and hydrolyzed by SAH hydrolase to form 
homocysteine. Homocysteine can undergo transmethylation via the enzyme methionine 
synthase (MS) and coenzyme 5-methyl-THF or by the enzyme betaine:homocysteine 
methyltransferase (BHMT) and coenzyme betaine. If SAM concentrations are high, B6-
de endent cystathionine ~3—synthase (CBS) is activated to shunt homocysteine into the p 
transsulfuration pathway and the eventual catabolism to cysteine and a-ketobutyrate. 
Abbreviations: BHMT, betaine:homocysteine methyltransferase; CBS, cystathionine ~—
synthase; DMG, dimethylglycine; GNMT, glycine N-methyltransferase; MAT, methionine 
adenosyltransferase; MS, methionine synthase; MTHFR, 5,10-methylenetetrahydrofolate 
reductase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine. 
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important part in cellular metabolism and are essential for the synthesis and methylation of 
DNA, production of membranes, and metabolism of lipids. A deficiency of any of these 
compounds may lead to decreased immunocompetence, increased hepatic lipid accumulation, 
reduced xenobiotic metabolism, and influence the risk of promotion of cancer by upsetting 
folate-dependent one-carbon and methyl group metabolism (16). 
The folate-dependent one-carbon cycle utilizes folate derivatives as important carbon-
donating molecules in the synthesis of DNA as well as the production of methionine de novo 
in methyl group metabolism. The dietary intake of folate and folic acid is essential to 
maintain homeostasis within the cycle as coenzymes and enzymes react to optimize folate's 
role in the health process. Folate's relationship with methyl ..group metabolism can ultimately 
affect homocysteine metabolism and the importance of this relationship becomes apparent 
with its connection with cardiovascular disease. 
Transfer of Methyl Groups into Methyl Group Metabolism 
The relationship between folate and homocysteine has become a subject of intense 
research in recent years because of an association with cardiovascular disease. 
Homocysteine is a highly reactive amino acid and has been shown to promote oxidative 
stress by increasing hydrogen peroxide production in cell culture (17). Homocysteine is 
either remethylated by 5-methyl-THF or betaine or is further metabolized in the 
transsulfuration pathway by the irreversible enzyme cystathionine (3-synthase (CBS) (15) 
(Figure 1.3). Homocysteine is protein-bound and present in low levels (7-24 µmol/L) in the 
blood and urine; consequently, disruptions to the folate-dependent and methyl group 
metabolism by congenital or nutritional disorders can cause an abnormal elevation of 
homocysteine concentration (as high as 200 µmol/L) in the plasma and urine. These states 
are known as hyperhomocysteinemia and hyperhomocysteinuria (18). The hepatocyte's 
homeostatic control in exporting accumulated homocysteine prevents cellular toxicity; 
however, the expelled homocysteine may leave vascular tissue in a threatening position 
because of its molecular characteristics (19). Homocysteine may jeopardize the vascular 
endothelium integrity by its ability to induce auto-oxidation of cholesterol and promote 
thrombosis (20). Kang et al. (21) showed that patients with coronary artery disease (CAD) 
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had significantly higher levels of homocysteine compared to those in the control group. The 
three enzymes involved with homocysteine metabolism work together and depend on the 
cellular concentration of SAM. MS or BHMT each metabolize approximately 27% of 
homocysteine, respectively, whereas the other 46% is transsulfurated by CBS (22). The 
regulatory control of SAM already demonstrated with MTHFR also inhibits BHMT from 
supplying methyl groups for methionine synthesis. An elevated SAM concentration also 
activates CBS to shunt homocysteine through the irreversible transsulfuration pathway 
(22,23). 
Homocysteine has a vital role in the relationship between the folate-dependent one-
carbon cycle and methyl group metabolism. It has been implicated in cardiovascular disease 
and the regulation of homocysteine metabolism depends on the cellular concentration of 
SAM and the enzymes involved with its metabolism. Homocysteine is either catabolized 
through the transsulfuration pathway or remethylated to form methionine and eventually 
form SAM, an important metabolite involved in the transmethylation of numerous biological 
compounds. 
Methyl Group Metabolism 
Methionine continues through the transmethylation pathway when ATP is hydrolyzed 
by the enzyme methionine adenosyltransferase (MAT) to release the adenosyl group that 
attaches to the sulfur of methionine, forming SAM (24). SAM can be seen as a function of 
methionine availability because of its biological activity and its ability to donate methyl 
groups in transmethylation reactions. It is found in both the cytosol and the mitochondria; 
however most of SAM-dependent transmethylation reactions take place in the cytosol (15). 
SAM is a biologically important metabolite that donates methyl groups in over 100 
reactions. Approximately 99% of SAM is demethylated in a multitude of reactions and 1 % is 
decarboxylated for polyamine biosynthesis and eventually converted back to methionine. 
SAM is an active metabolite in that it helps to control the interactions between folate-
dependent one-carbon cycle and methyl group metabolism. As previously stated, when SAM 
is in high concentration, it acts as an inhibitor to the enzyme BHMT to slow the production 
of methionine as well as inhibiting MTHFR activity to prevent the availability of 5-methyl-
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THE for the remethylation of homocysteine. High SAM concentrations also facilitate the 
disposal of homocysteine through the transsulfuration pathway activating CBS and 
normalizing homocysteine concentration (25). As a universal donor of methyl groups, SAM 
donates its activated methyl group via a variety of methyltransferases and is converted to S-
adenosylhomocysteine (SAH) (Figure 1.3). The ratio of SAM to SAH is indicative of the 
transmethylation potential due to the ability of SAH's potent inhibition of transmethylation 
reactions (26). A study by Caudill et al. (27) examined the SAM: SAH ratio and found there 
was a positive correlation between plasma homocysteine concentration and SAH levels in a 
CBS enzyme knockout mouse model. SAH may be a reliable index of transmethylation 
potential versus increased SAM concentration or -the SAM: SAH ratio and that plasma 
homocysteine could be a good indicator of disturbance within methyl group metabolism. 
Products from the transmethylation reaction are too numerous to list, but the enzymes for 
these reactions are categorized into two groups: those involved in biosynthesis and 
degradation of bioactive amines, and those involved in bulk metabolic transformations (28). 
Major examples of the first group include epinephrine, phosphatidylcholine, and the 
modulation of DNA and RNA (29). An example of the second group involves creatine 
synthesis that constitutes the majority (~75%) of transmethylatzon reactions. 
The products from the transmethylation reaction that occur in methyl group 
metabolism convey the importance of this pathway in the health process. Regulation is 
essential to maintain the SAM : SAH ratio to optimize the transmethylation potential; 
fortunately, there is an enzyme available to perform this function. 
Properties of Glycine N-metlayltransferase 
The enzyme glycine N-methyltransferase (GNMT) uses the methyl group from SAM 
in the transmethylation reaction to produce sarcosine, a compound synthesized by that has no 
known metabolic function (Figure 1.3) (30). GNMT utilizes glycine as a methyl acceptor 
(31) and comprises about 0.9-3.0% of soluble protein in the liver (32). GNMT was first 
discovered in 1960 by Blumenstein and Williams and is known to be part of a system that 
regulates the SAM: SAH ratio (33). SAH is the product of SAM demethylation and has an 
instrumental role in regulation of the transmethylation reaetion from its ability to inhibit 
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almost all of the methyltransferase enzymes. However, GNMT is not affected by SAH and 
optimizes the transmethylation potential (26). Heady and Kerr (34) found that the absence of 
GNMT activity in rabbit fetal liver and tumor tissue led to elevated levels of tRNA 
methyltransferase compared to normal adult tissue. The GNMT gene expression is also 
down-regulated in human hepatocellular carcinoma (HCC) cell lines as well as in liver tissue 
of HCC patients (35,36). GNMT has its own regulation, but in a different manner than other 
methyltransferases. Cook and Wagner (37) found that 5-methyl-THF can tightly bind 
GNMT but the function of this action was uncertain. Further research has shown that 
GNMT's highly specific binding to 5-methyl-THF serves as an allosteric inhibitor of GNMT 
activity and can occur in 5-methyl-THF concentrations that are similar to what is found in the 
liver (5.1 x 10-~ M showed virtually complete inhibition) (30). To summarize this regulation, 
low SAM levels result in increased MTHFR activity, thereby producing 5-methyl-THF that 
inhibits GNMT and allow SAM concentrations to increase and participate in biologically 
important transmethylation reactions (Table 11). When SAM concentrations increase 
beyond metabolic needs, it binds to MTHFR and inhibits its activity, thus decreasing the 
concentration of 5-methyl-THF. This action allows unbound GNMT to dispose of SAM and 
lower the SAM concentration. 
Active GNMT is composed of four subunits with a denatured molecular weight of 
31,500 kD, determined using the SDS-PAGE technique (31). Cell culture studies have 
shown that unbound GNIVIT monomers in the cytosol are covalently phosphorylated by a 
cAMP-dependent protein kinase and ATP, forming a tetramer and producing a ~2 fold 
increase in enzymatic activity (38). The disassociation of the tetrameric traits produces a loss 
in activity and the monomer units can then be transported into the nucleus and bind to 
chromatin (39). Raha et al. (40) discovered that GNMT is also responsible for activity 
associated with the cytochrome P-4501 A 1 (CYP 1 A 1) system within the nuclei of hepatoma 
H4IIE cell line. Formerly known as 4S polycyclic aromatic hydrocarbon (PAH)-binding 
protein, GNMT in dimeric form in the nucleus acts as a PAH-binding protein that has the 
ability to mediate the induction of CYP 1 A 1 (41). GNMT plays an important role in methyl 
group metabolism and an uncontrolled- increase in its activity can perturb folate-dependent 
one-carbon and methyl group metabolism as shown later in this thesis. 
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Table 1.1 Regulation and perturbations of enzymes 







Influences on Activity 
Decrease: high SAM concentration; increased protein intake 
Increase: high SAM concentration; glucocorticoids 
Decrease: B6 deficiency; insulin; genetic polymorphisms 
Increase: high SAM concentration; increased protein intake; 
retinoids; glucocorticoids; growth hormone 
Decrease: high 5-methyl-THF concentration 
Decrease: Bl2 deficiency; increased protein intake; genetic 
polymorphism 
Decrease: high SAM concentration; B2 deficiency; genetic 
polymorphisms 
Abbreviations: BHMT, betaine:homocysteine methyltransferase; CBS, cystathionine ~3—
synthase; GNMT, glycine N-methyltransferase; MAT, methionine adenosyltransferase; MS, 
methionine synthase; MTHFR, 5,10-methylene-THF-reductase. 
Homocysteine Metabolism and the Transsiclfi~ration Pathway 
During basal metabolic conditions, homocysteine cycles 1.5-2.0 times through the 
remethylation pathway (19). The enzyme SAH hydrolase catalyzes the hydrolysis of SAH to 
form homocysteine and adenosine (Figure 1.3). Because this enzyme is reversible and the 
equilibrium favors SAH synthesis, the rate of SAH hydrolysis depends on the removal of 
homocysteine either through remethylation or transsulfuration. As explained earlier, SAH is 
a potent inhibitor of methyltransferases and the SAM: SAH ratio is often used as an indicator 
of methylation capacity (26). As the ratio increases due to high SAM levels, CBS is 
activated to reduce homocysteine and normalize the SAM: SAH ratio (25). The complete 
transsulfuration pathway is not as wide spread in the body as folate-dependent one-carbon 
and methyl group metabolism and occurs only in the liver, kidneys, small intestine, and 
pancreas. When the B6-dependent enzyme CBS is activated by a high SAM concentration, 
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the irreversible CBS enzyme attaches a serine to homocysteine to form cystathionine. CBS 
activity is also dependent on another factor; cell culture experiments have shown that heme 
produces an oxidative state, which increases CBS activity (42). The B6-dependent enzyme y-
cystathionase cleaves cystathionine into 3 molecules: cysteine, a-ketobutyrate, and 
ammonium. Cysteine can be oxidized to taurine, used in the synthesis of glutathione, or as a 
precursor of pyruvate. Ammonium is excreted from the body through the kidneys and a-
ketobutyrate is an intermediate substrate that is converted to propionyl-CoA and then to 
succinyl-CoA in the citric acid cycle. 
Homocysteine is the branch point in folate-dependent one-carbon and methyl group 
metabolism and is either remethylated or undergoes transsulfuration in response to the 
cellular concentration of SAM. A few examples of the disruption of homocysteine 
metabolism have been demonstrated to show the relevance of homocysteine in response to 
health and disease. The regulation of these two interrelated pathways is important to address 
and should be considered in relation to diseases that may occur from disruptions. 
Disruption of Folate and Methyl Group Metabolism 
Under basal conditions, folate-dependent one-carbon and methyl group metabolism is 
tightly regulated and the body remains in a healthy state. ,When this system is perturbed, 
various diseases may occur; therefore, it is important to study the multitLide of genetic and 
nutritional factors as well as pharmacological agents that can perturb its controlled 
environment. Folate and its role in methyl group metabolism is important in understanding 
how a disruption in the pathway can produce various detrimental outcomes. Table l . l 
summarizes some of _the enzymes affected by disturbances in the pathway. 
Genetic Enzyme ~'olymo~p/zisms 
Genetic enzyme polymorphisms are present in folate-dependent one-carbon and 
methyl group metabolism and these disruptions can cause health problems if left uncontrolled 
or perturbed by a nutritional deficiency. MS, CBS, and MTHFR enzyme polymorphisms 
have been extensively researched and different variants within each, enzyme are established. 
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A common and extensively researched enzyme polymorphism that is found in folate 
metabolism is the enzyme MTHFR. This genetic polymorphism is caused by the C —~ T 
substitution at base pair 677 and causes a valine to substitute for an alanine, resulting in 
reduced stability under increases in temperature; therefore, thermolability is a fundamental 
characteristic of this polymorphism (43). This autosomal recessive mutation is characterized 
by hyperhomocysteinuria and hyperhomocysteinemia. Clinically, people with severe cases 
develop neurological abnormalities and atherosclerotic damage and often early death, while , 
mild cases can be troubled with clinical vascular disease in adulthood (44}. In a case study 
by Kanwar et al. (45), a mentally retarded 10-year-old chicd with homocystinuria exhibited 
no hepatic MTHFR activity. Additionally, the patient displayed distortions in the endothelial 
cells, deleterious changes in the brain and liver tissue, and demyelination of striated muscle 
and kidneys. A study investigating CAD cases showed that 6 out of 21 patients had 
thermolabile MTHFR that resulted in decreased enzyme activity. Of these 6 patients, 2 had 
high plasma homocysteine levels and suboptimal folate levels (44). A study by Silaste et al. 
(46) found that folate supplementation improved plasma homocysteine levels; healthy 
women (22-57 y) participated in a 5-week crossover study in which they consumed high (6,00 
µg/day) and Iow (220 µg/day) folate diets. These women were tested for polymorphic 
enzymes and those with the MTHFR mutation on the high folate diet showed a decrease in 
plasma homocysteine levels but a continued suboptimal plasma folate level. The high folate 
diet did not affect plasma homocysteine levels of people with CBS or MS polymorphisms. A 
study performed by Kluijt~nans et al. (47) also examined the three enzyme polymorphisms 
and their different variants in 452 young adults. The frequency of the enzyme 
polymorphisms MTHFR (2 types 677TT and 1298CC) occurred 13.5% and 10.6% 
respectively, MS (275 6GG and 66GG) occurred 2.0% and 29.6% respectively, and CBS (1 
type 844ins68 WI) occurred 17.7%. Of these enzyme deficiencies, MTHFR 677TT was the 
only one to have an increase in subjects' plasma homocysteine concentration and a decrease 
in serum folate levels. The authors conclude that 35% of the variability involved in plasma 
homocysteine concentration could be attributed to folate and B 12 concentrations, implicating 
the importance of nutrition on human health, even at a young age. 
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The MS enzyme polymorphism has been researched for its. impact on the 
remethylation of homocysteine in methyl group metabolism but has not been shown to have 
the detrimental impact that MTHFR and CBS polymorphisms display (4$,49). However, the 
genetic polymorphism of the CBS enzyme does perturb homocysteine metabolism and can be 
detrimental. The CBS enzyme deficiency is caused by an autosomal recessive mutation and 
is the most common cause of hyperhomocysteinemia with fasting plasma homocysteine 
levels as high as 200 µmol/L. These elevated levels cause mental retardation, Marfan-like 
habits, osteoporosis, ectopic lentis, and thromboembolic disease. A CBS knockout mouse 
model using a homozygous mutant exerted a dramatic increase in plasma homocysteine 
levels and increased SAH concentration in various tissues compared to heterozygous wild-
type mice (50). A clinical report by Yaghmai et al. (51) described the symptoms of a 10-
year-old patient with CBS deficiency that was on an unrestricted diet and was undergoing 
betaine therapy to treat hyperhomocysteinemia. Methionine toxicity developed and she 
suffered from cerebral edema, pancreatitis, and mild bradycardia. After stopping the betaine 
therapy, restricting methionine intake and supplementing her diet with folate, B6, and B 12, her 
plasma methionine and homocysteine levels returned to baseline and all adverse symptoms 
disappeared. 
The conversion of homocysteine to cystathionine occurs in the brain and impaired 
CBS activity and folate deficiency in brain cells may cause accumulated homocysteine to 
promote excitotoxicity, stimulating N-methyl-D-aspartate receptors and damaging neuronal 
DNA. Such conditions may disrupt brain development in children and could have a role in 
neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, schizophrenia, 
and depression (52). 
There are genetic enzyme polyTmorphisms present throughout the one-carbon cycle 
and methyl group metabolism. The lack of activity in the enzymes CBS and MTHFR has 
been implicated in increased homocysteine concentrations in the plasma and urine, which are 
correlated to a heightened risk for cardiovascular disease. Researching the influence of diet 




If homocysteine metabolism is disrupted by a genetic disorder, SAH concentration 
increases, perturbing the SAM: SAH ratio and disrupting the cellular methylation potential 
(26). A deficiency in folate, methionine, choline, or B12 could exacerbate this situation in the 
remethylation pathway of homocysteine while a deficiency in B6, which aids in the activity 
of CBS and y-cystathionase could decrease the shuttling of homocysteine through the 
transsulfuration pathway (53). 
Hyperhomocysteinemia has been identified as an independent risk factor for vascular 
disease and multiple studies have looked at folate intake and its influence on plasma 
homocysteine concentration. A study by Pancharuniti et al. (54) compared 108 white males 
with angiographically demonstrated CAD to age-related controls and concluded that an 
increased risk of CAD was present in patients with the lowest level of plasma folate 
concentration, which was inversely related to their plasma homocysteine concentration. In 
addition, vitamin B12 plasma levels had no correlation with CAD. Van Oort et al. (55) 
demonstrated that folate supplementation in 316 healthy men and women (50-75 y) 
decreased plasma homocysteine levels in adose-dependent fashion with 392 µg/day as the 
lowest dose to produce a positive homocysteine reduction. Brouwer et al. (56) examined the 
impact of natural folate versus folic acid supplements in healthy men and women (18-45 y). 
The subjects received a dietary intake of either a placebo and low folate diet 0210 µg/day), a 
placebo and high folate diet mainly from vegetables and citrus fruit 0560 µg/day), or a folic 
acid supplement and low folate diet 0560 µg/day). After 4 weeks, showed that plasma 
folate status improved and plasma homocysteine concentrations decreased in the high 
folate/folic acid groups compared to the control group. These results indicate that dietary 
folate and folic acid supplements are both able to reduce plasma homocysteine levels. 
The lack of dietary methyl groups has been linked to tumor induction and is well 
documented. The lipotropes methionine, choline, and folate are essential to the folate-
dependent one carbon pool and methyl group metabolism and when a diet is deficient in 
these nutrients, it will induce tumors without the aid of an outside carcinogen (57). A study 
by Miller et al. (58) examined the folate-repletion activity in rats that were fed a folate-
deficient diet for 4 weeks. There was a 10-fold increase in plasma homocysteine 
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concentration and a 3 -fold decrease in hepatic SAM levels in folate-deficient rats compared 
to the control group. The authors attribute these findings to an impaired remethylation 
capacity and inactivation of CBS activity. Interestingly, folate repletion returned the 
homocysteine levels to baseline correlating to the incremental folate doses given. 
Additionally, ethionine injections were administered to the folate-depleted rats for 3 days to 
test the efficacy of inducing homocysteine catabolism without increasing SAM. Ethionine 
was converted to S-adenosylethionine and caused a 300% increase in CBS activity and 
lowered the plasma homocysteine levels. 
Cook et al. (59) demonstrated the impact of rats fed amethyl-deficient diet in which 
homocysteine was added in place of methionine in the diet. Weights significantly. decreased 
throughout the 5 weeks in rats on the deficient diet even though both groups consumed 
similar amounts of diet. The livers of the methyl-deficient group had an increased fat 
concentration, decreased GNMT activity, slightly decreased SAM concentration, and SAH 
concentration was elevated as homocysteine was rapidly converted to SAH. . The treatment 
group ingested the control diet for the Last week and showed an increase in GNMT activity. 
The perturbations seen in methyl group metabolism from amethionine-deficient diet has 
implications on DNA that affect the entire health process. The disruption of SAM's ability to 
methylate DNA will cause progressive dysregulation of DNA methylation, priming the stage 
for tumor promotion (60). 
A deficiency in the dietary intake of the folate can have a profoLtnd effect on the 
folate-dependent one-carbon pool and methyl group metabolism. The preceding paragraphs 
examined the importance of dietary folate or folic acid in the regulation of homocysteine 
metabolism and its inverse relationship to plasma homocysteine concentration. Nutritional 
deficiencies of the lipotropes methionine and choline in addition to low folate intake can 
disrupt enzyme activity and the cellular concentration of metabolites within the interrelated 
cycles and are implicated in hepatocarcinoma. When additional perturbations are present, the 
risk of disease is heightened. Whether the disruption comes from an exogenous source (i.e., 
drugs, alcohol) or comes from endogenous conditions (i.e., hormones), the harmful 




Fluctuations in hormones influence enzyme activity and can perturb coenzymes 
within methyl group metabolism. Glucocorticoids are hormones secreted from the adrenal 
cortex that elevate blood glucose and can mediate adiabetic-like state. The induction of 
diabetes or the application of glucocorticoids may have an effect on CBS activity and its 
protein levels. Cell culture research using the H4IIE cell line showed that synthetic 
glucocorticoids increased CBS enzyme protein and mRNA levels while insulin inhibited this 
effect, providing insight that insulin may have an influential role in homocysteine 
metabolism (61). Ratnam et al. (61)used a streptozotocin-induced diabetic rat model that 
exhibited increased hepatic CBS activity and mRNA protein that was reversed by the 
application of insulin; the induction of CBS activity and mRNA was not found in the 
kidneys. Hyperglucagonemic rats (which displayed increased CBS activity and protein 
abundance) exhibited no change in hepatic methionine concentration but there was a 
significant decrease in both plasma and hepatic homocysteine levels (62). The diabetic drug 
troglitazone, which enhances insulin activity, was administered to lean and overweight rats 
and the drug may have aided in the hepatic uptake of homocysteine from the plasma, 
decreasing plasma homocysteine concentrations and causing a dramatic increase in hepatic 
CBS enzyme activity in both rat groups (63). However, these homocysteine reductions may 
not occur in diabetic cases where renal insufficiency is present, a condition strongly 
associated with hyperhomocysteinemia (64). 
While the enzyme GNMT is found predominately in the periportal region of the liver, 
its prevalence in methyl group regulation is also found in the proximal convoluted tubules of 
the kidney and the exocrine pancreas of both rabbit and rat, regions that are known for 
gluconeogenic activity (65,66). In alloxan-induced diabetic sheep, the activity of GNMT 
was significantly increased as well as y—cystathionase compared to the control, suggesting an 
exaggerated homocysteine catabolism in a diabetic state (67). Jacobs et al. (62) showed 
similar conclusions using hyperglucagonemic rats that resulted in increased hepatic GNMT, 
CBS, and ~—cystathionase enzyme activity, concluding that glucagon increases intracellular 
concentrations of CAMP and was responsible for the increased CBS mRNA levels. Rowling 
and Schalinske (68) showed in cell culture that the treatment of the H4IIE cell line with 
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cAMP appeared to attenuate glucocorticoid-mediated induction of GNMT protein 
abundance. In the rat model, the synthetic glucocorticoid dexamethasone induced GNMT 
activity and- protein abundance as it decreased plasma homocysteine levels versus the control 
treatment. Aida et al. (~9) found that the administration of growth hormone on 
hypophysectomized male mice reduced GNMT mRNA expression whereas female mice 
were not affected as much, indicating a difference between male and female mice while 
growth hormone is seen as another influence on GNMT regulation. 
The regulation of enzymes in methyl group metabolism ultimately affects the cellular 
concentration of metabolites that are involved in the creation of biological products. 
Whether it involves GNMT activity in regards to SAM in the transmethylation reaction or 
homocysteine metabolism in relation to CBS and -cystathionase activity, the influence of 
hormones to these enzymes in a derogatory manner can perturb the pathway and may be 
Linked to cardiovascular disease and cancer. Disruptions to the folate-dependent one-carbon 
pool and methyl group metabolism from the addition of exogenous factors can also be 
implicated in the development of disease. 
Dracg-Nutrient Interactions 
The classic folate antagonist drug model is found in the area of cancer treatment. 
Folate analogs are often given to slow the increased rate of DNA synthesis in cancerous cells. 
An example of this is methotrexate, an anticancer drug that inhibits the conversion of DHF to 
THF. The use of methotrexate results in an intracellular depletion of folate metabolites and 
reduced the carbon flow from 5-methyl-THF to homocysteine (70). 
The application of antiepileptic drugs has frequently exhibited low plasma folate and 
high plasma homocysteine concentrations. Apeland et al. (71) found a decrease in plasma 
vitamin B6 concentration in patients taking antiepileptic drugs; implying abnormal 
homocysteine metabolism and increasing the chance of diseases associated with high 
homocysteine concentrations. Pregnant women taking antiepileptic drugs have an increased 
chance of NTDs and Weber et al. (72) has shown the importance. of folic acid 
supplementation as an effective preventative measure to this population. 
20 
Another factor that results in perturbations to methyl group metabolism is ethanol 
intake. In long-term administration, it has been shown that as the catabolism of methionine 
is increased by decarboxylation, leading to decreased SAM levels, and increased BHMT 
activity concurrent with decreased MS activity. GNMT activity decreased but only in the 8t" 
week of ethanol intake versus weeks 2 and 4 (73). After a single dose of ethanol (3 gikg 
BW), hepatic SAM concentration decreased in rats concurrently with inhibited CBS activity; 
enzymes involved in glutathione production were inhibited and decreased hepatic glutathione 
concentration did not return to control levels for 24 hr (74). 
The influence of drugs and alcohol on folate and methyl group metabolism is 
profound. The overconsumption of alcohol is well known for its effect on the liver and 
antiepileptic drugs decrease plasma folate levels, subsequently leading to increased plasma 
homocysteine levels and the increased risk for NTDs. There are other drugs that are 
prescribed by doctors that have an impact on methyl group metabolism and the folate pool 
that are not as well known. Retinoids used in cancer treatment and dermatology are 
emerging as one of these such drugs. 
Retinoid Implications 
Retinoids are derived from the fat-soluble vitamin A. Vitamin A is important in 
growth and overall health but is considered toxic in high doses. A study by Fell and Steele 
(75) found that the intake of 1000 IU (0.3 mg) of retinol acetate/gm diet for 10-14 days 
suppressed MTHFR activity, resulting in decreased 5-methyl-THF levels and decreased 
SAM concentrations. The vitamin A derivative 13-cis-retinoic acid (CRA), which is more 
biologically active than retinol acetate, can increase serum triglyceride levels and hepatic 
lipids while perturbing methyl group metabolism by reducing hepatic SAM concentration 
and affecting the SAM: SAH ratio (76). However, CRA's increased biological activity has 
made it an effective agent in the dermatology field. CRA's success in the treatment of 
common skin disorders such as severe acne and psoriasis has produced synthetic retinoids 
like Accutane0 and Tegison0 and its use is widespread in dermatology. The frequent causes 
of acne are reduced from retinoid facilitation on the de-differentiation of sebaceous glands, 
sebum gland production suppression, and promotion of shedding lceratinocytes (77). These 
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drugs are taken orally and are given when topical treatments do not work. The number of 
retinoid prescriptions has steadily increased in the past ten years as doctors are prescribing 
therapeutic retinoids for moderate acne as well (78). Oral retinoids are administered in doses 
ranging from 0.5-2.0 mg/kg BW (2-7 µmol/kg BW) for an average of 4-5 months. Adverse 
effects are seen in 100% of users in the form of skin and lip dryness, eczema, and hair 
shedding which subside within 3 weeks of treatment. Plasma triglyceride levels as well as 
cholesterol has been shown to increase with synthetic retinoid use, therefore patients are 
screened before starting retinoid therapy and at 2-4 week intervals (77). The most 
biologically active retinoid is all-trans-retinoic acid (ATRA) and is used clinically in the 
treatment of acute promyelocytic leukemia in a dosing regime similar to CR.A. Rowling and 
Schalinske (79) found an increase in GNMT activity and protein abundance after 10 days of 
ATRA treatment (30 µmol/kg BW) in rats. Retinoids in the form of retinyl palmitate, CR.A, 
and ATRA have all been shown to induce both GNMT activity and protein abundance and 
caused DNA hypomethylation in rats when administered in pharmacological doses for a short 
time period (10 d) (80). Even though the folate-dependent one-carbon pool and methyl 
group metabolism is found in the pancreas and kidneys, McMullen et al. (81) did not show 
increases in GNMT activity or protein abundance in rats in these two tissues as seen in the 
Iiver after ATRA application (30 µmol/kg BW for 10 d). There was also an increase in 
GNMT activity in male versus female rats even though both groups were dosed and treated 
in the same manner. 
Researching the impact that retinoids have on methyl group metabolism is in its 
initial stages and the overall outcome remains to be seen. A relationship between the 
pharmacological dose of ATRA on rats and the doses given in clinical settings has not been 
established. The studies in Chapter 2include adose-response and atime-course study of 
ATRA's affect on folate and methyl group metabolism in an attempt to bridge this gap. The 
folate-dependent one-carbon pool and methyl group metabolism's involvement in NTDs, 
cancer, and cardiovascular disease is prevalent but the mechanisms in the progression of 
these diseases are not completely known. Recently, research has shown that hormones 
involved in glucose metabolism have an effect on methyl group metabolism and this 
relationship may help explain anomalies within both pathways. Disruption to methyl group 
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metabolism by ATRA has shown to be an effective model in understanding this pathway and 
may someday provide insight to the diseases and disorders associated with the folate-
dependent one carbon pool and methyl group metabolism. 
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CHAPTER 2. ALL-TRANS-RETINOIC ACID RAPIDLY INDUCES 
GLYCINE N-METHYLTRANSFERASE IN ADOSE-DEPENDENT 
MANNER AND REDUCES CIRCULATING METHIONINE AND 
HOMOCYSTEINE LEVELS IN RATS 
A paper accepted by the Journal of Nutrition 
Marlies K. Ozias and Kevin L. Schalinske 
Abstract 
Glycine N-methyltransferase (GNMT) regulates the methyl group supply for S-
adenosylmethionine-dependent transmethylation reactions. Retinoids have been shown to 
perturb methyl group metabolism by increasing the abundance and activity of GNMT, 
thereby leading to the loss of methyl groups. Previous studies used pharmacological doses 
(30 µmol/kg BW) of various retinoids administered daily for a total of 10 d. Here, we 
examined the dose- and time-dependent relationship between all-Mans-retinoic acid (ATRA) 
administration and induction of GNMT, as well as determining additional indices of .methyl 
group and folate metabolism. For the dose-response study, rats were given either 0, 1, 5, 10, 
15 or 3 0 µmol ATRA/kg BW for 10 d. For the time-course study, rats received 3 0 µmol 
ATRA/kg BW for 0, 1, 2, 4, or 8 d. A. significant increase (1 OS%) in GNMT activity was 
observed with doses as low as 5 µmol/kg BW, whereas maximal induction (231 %)of GNMT 
activity was achieved at 30 µmol/kg BW. Induction of hepatic GNMT by ATRA was rapid, 
exhibiting a 31 %increase following a single dose (1 d) and achieving maximal induction 
(95%) after 4 d. Plasma methionine and homocysteine concentrations were decreased 42 and 
53%, respectively, in ATRA-treated rats compared to control values. In support of this 
finding, the hepatic activity of methionine synthase, the folate-dependent enzyme required 
for homocysteine remethylation, was elevated 40% in ATRA-treated rats. This work 
demonstrates that ATR.A administration exerts a rapid effect on hepatic methyl group, folate, 
and homocysteine metabolism at doses that are within the therapeutic range used by humans. 
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Introduction 
Methyl group and folate-dependent one-carbon metabolism play an important role in 
the methylation of phospholipids, neurotransmitters, proteins, and nucleic acids (1,2). These. 
interrelated pathways provide the needed methyl groups for numerous transmethylation 
reactions that ultimately affect human health, Transmethylation reactions in methyl group 
metabolism results in the production of S-adenosylhomocysteine (SAH) from S-
adenosylmethionine (SAM) (Figure 2.1). Following hydrolysis of SAH, the resulting 
homocysteine can undergo transsulfuration to produce cystathionine, which can eventually 
be metabolized to cysteine and glutathione, as well as other important compounds. 
Alternatively, remethylation of homocysteine and the concomitant conversion of ~-
methyltetrahydrofolate (5-methyl-THF) to tetrahydrofolate (THF) from the folate-dependent 
one-carbon pool results in the regeneration of methionine, the precursor for SAM (2). An 
inability to metabolize homocysteine by either transsulfuration and/or transmethylation leads 
to increased plasma levels, a characteristic associated with thromboembolic diseases and 
disruption of vascular wall maintenance (3,4). 
A number of regulatory mechanisms function to maintain optimal metabolism of 
folate, methyl groups, and homocysteine. SAM allosterically inhibits 5,10-
methylenetetrahydrofolate reductase (MTHFR), the enzyme that irreversibly produces 5-
methyl-THF for the subsequent remethylation of homocysteine, a reaction that requires the 
B12-dependent enzyme methionine synthase (MS) (5,6). SAM also serves as a positive 
modulator of cystathionine (3-synthase, the enzyme that catalyzes the formation of 
cystathionine from homocysteine as the initial step in the transsulfuration pathway (7). 
Regulation is also maintained by the action of glycine N-methyltransferase (GNMT), a key 
cytosolic enzyme that converts glycine to sarcosine to regulate the utilization of methyl 
groups and optimize the ratio of SAM: SAH (2,8). Because SAH is a potent inhibitor of 
most methyltransferases (9), the ratio of SAM: SAH and its regulation by GNMT controls 
transmethylation processes. GNMT is also a folate-binding protein that is allosterically 


















FIGURE 2.1 Methyl group, homocysteine and folate metabolism. S-adenosylmethionine 
(SAM) serves as the methyl group donor in numerous transmethylation reactions (X —~ X-
CH3), resulting in the formation of S-adenosylhomocysteine (SAH) and eventually be 
converted to homocysteine. Homocysteine can be catabolized through the transsuifuration 
pathway, or remethylated back to methionine by the action of the B12-dependent enzyme, 
methionine synthase (MS). This latter reaction is dependent on the one-carbon pool to 
supply the necessary methyl group from 5-methyl-THF, irreversibly generated by the 
reduction of 5,10-methylene-THF via 5,10-methylene-THF-reductase (MTHFR). Glycine N-
methyltransferase (GNMT) regulates the SAM: SAH ratio and transmethylation potential by 
disposing of methyl groups in the form of sarcosine under conditions of excess. For further 
regulation of methyl group supply, SAM is an allosteric inhibitor of MTHFR, whereas 5-
methyl-THF inhibits the activity of GNMT. Abbreviations : GNMT, glycine N-
methyltransferase; MS, methionine synthase; MTHFR, 5,10-methylene-THF-reductase; 
SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine. 
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Thus, modulation of any of these regulatory mechanisms has the potential to disrupt the 
metabolism of folate, methyl groups, or homocysteine. 
We have shown that retinoids such as all-trans-retinoic acid (ATR.A) have the ability 
to perturb methyl group metabolism by increasing the activity and abundance of GNMT, 
thereby leading to the loss of methyl groups required for other biological processes (13 -16). 
These studies utilized large doses of ATRA (3 0 µmol/kg B W) administered for at least 7-10 
d. Thus, it is important to examine lower doses that are more relevant to human usage, as 
well as the length of treatment with ATRA. In the work presented here, we examined the 
dose- and time-dependent relationship between ATRA and the induction of GNMT as we11 as 
parameters associated with folate and homocysteine metabolism. 
Materials and Methods 
Chemicals and reagents. - 
Reagents were obtained from the following: S-adenosyl-L-[methyl-3H]methionine, 
-New' England Nuclear (Boston, MA); phenylmethylsulfonyl fluoride and ATR.A, Calbiochem 
(La Jolla, CA); goat anti-rabbit immunoglobulin G horseradish peroxidase, Southern 
Biotechnology (Birmingham, AL}; ECL Western blotting detection reagents, Amersham 
Pharmacia (Piscataway, NJ); and S-adenosyl-L-methionine, Sigma Chemical (St. Louis, 
MO). GNMT antibody was provided by Y-M.A. Chen, National Yang-Ming University, 
Taipei, Taiwan (17). All other chemicals were of analytical grade. 
Animals and diet. 
All animal experiments were approved by and conducted in accordance with Iowa 
State University Laboratory Animal Resources Guidelines. For all studies, male Sprague-
Dawley (Harlan Sprague-Dawley, Indianapolis, IN) rats (50-74 g) were housed in plastic 
cages in a room with a 12-h light: dark cycle and fed a control diet as described (16). Rats 
were acclimated to the control diet and the oral administration of corn oil for 3 d. For the 
dose-response study, ATRA was orally administered at 0, 1, 5, 10, 15, and 30 µmol/kg BW 
using corn oil as the vehicle for a total of 10 d. For the time-course study, rats received 
33 
either ATRA (3 0 µmol/kg B W) for 1, 2, 4, or 8 d or vehicle (0 and 8 d) . At the end of the 
treatment period, rats were anesthetized and whole blood was obtained via cardiac puncture 
for determination of plasma methionine and homocysteine concentrations. Liver samples 
were obtained for determining the enzymatic activity and abundance of GNMT and folate 
coenzyme concentrations, as well as the enzymatic activity of MTHFR and MS. 
Measurement of GNMT activity. 
GNMT enzymatic activity was assayed as described by Cook and Wagner (10) with 
minor modifications. Portions of liver were homogenized in three volumes of ice-cold 
phosphate buffered (10 mmol/L, pH 7.0) sucrose (0.25 mol/L) containing 1 mmol/L EDTA, 
1 mmol/L sodium azide, and 0.1 mmol/L phenylmethylsulfonylflouride. After centrifugation 
(20,000 x g for 30 min), supernatants were stored with 2-mercaptoethanol (10 mmol/L) at —
70° C. The assay contained 1 mol/L Tris buffer (pH 9.0), 5 mmol/L dithiothreitol, 10 
mmol/L glycine, and 1 mmol/L S-adenosyl-L-[methyl-'H]methionine (47.7 kBq/µmol) and 
the reaction was initiated with 250 µg of the protein supernatant. For the determination of 
total soluble protein in the tissue extract, a commercial kit (Coomassie Plus, Pierce, 
Rockford,. IL) based on the method of Bradford (18) was used with bovine senim albumin as 
a standard. 
Measurement of GNMT protein abundance. 
GNMT protein abundance was determined using immunoblotting procedures 
previously described (16). A 10-20% gradient SDS-polyacrylamide gel was used for the 
separation and subsequent determination of the GNMT monomer subunit (32 kDa) 
abundance. After separation, proteins were transferred to a nitrocellulose membrane and 
incubated for a minimum of 6-24 h with a monoclonal GNMT antibody (17) at 4 °C followed 
by 1 h incubation at room temperature with goat anti-rabbit horseradish peroxidase secondary 
antibody. Chemiluminescence detection was used to determine GNMT protein abundance 
following exposure to Kodak X-Omat AR film. Densitometric analysis was preformed using 
SigmaGel Software (SPSS, Chicago, IL). 
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Homocysteine analysis. 
Plasma total homocysteine concentrations were determined according to the method 
of Ubbink et al. (19). In brief, heparinized blood from the cardiac puncture was immediately 
centrifuged (3,800 x g for 6 min) and plasma samples were stored at —70° C until 
derivatization. For derivatization, N-acetylcysteine (1 mmol/L) was added as an internal 
standard to 300 µL of plasma. An equal volume of 100 mL/L tributylphosphine in 
dimethylformamide was added followed by incubation at 4 °C for ~0 min. The reaction was 
stopped with 100 mL/L trichloroacetic acid — 1.0 mmol/L EDTA and following 
centrifugation at 1,000 x g for 5 min, the supernatant was added to a solution containing 
borate buffer (0.125 mol/L, pH 9.5), sodium hydroxide (1.55 mol/L), and 4-fluoro-7-
sulfobenzofurazan (1 g/L). Samples were filtered and analyzed by HPLC using fluorometric 
detection and a mobile phase consisting of 960 mL/L potassium phosphate (0.1 mol/L, pH 
2.1) buffer and 40 mL/L acetonitrile. 
Determination of hepatic folate coenzyme concentrations. 
THE and 5 -methyl-THF were determined using HPLC and fluorometric detection 
according to Rebello (20) with some minor modifications. Briefly, portions of liver were 
homogenized in 4 volumes of ice-cold sodium acetate buffer (0.1 mol/L, pH 4.9) containing 
5 mL/L ascorbate and 20 mmol/L 2-mercaptoethanol under a steady stream of nitrogen, 
tightly capped, and stored at —70 °C until analysis. Samples were placed in a boiling water 
bath for 60 min and following centrifugation at 20,000 x g for 10 min, rat serum conjugase 
was added to an aliquot of the resulting supernatant and incubated in a shaking water bath for 
1 h at 37 °C. Following activation of Sep-Pak NH2 columns with acetonitrile and sodium 
acetate buffer (16 mmol/L, pH 4.5), samples were applied and washed with acetate buffer 
and sodium phosphate (0.1 mol/L) containing 50 mmol/L 2-mercaptoethanol. Folate 
coenzymes were separated on a Phenyl Radial-Pak column (waters, Milford, MA) and 
quantified using fluorometric detection. A gradient mobile phase operated at 2.0 mL/min 
consisted of: 760 mL/L sodium phosphate (0.1 moI/L, pH 7.5) — 240 mL/L acetonitrile for 4 
min; a linear gradient (2 min) to 5 00 mL/L — 5 00 mL/L and maintained from 6 to 10 min; a 
linear gradient (2 min) to 100 mL/L — 900 mL/L and maintained from 12-16 min; and a 
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linear gradient (2 min) back to initial conditions (760 mL — 240 mL/L) for up to 20 min to re-
equilibrate the column. 
MTHFR determination. 
The .activity of MTHFR was determined in Liver samples as previously described 
(21,22). Briefly, portions of liver were homogenized in 4 volumes of ice-cold potassium 
phosphate buffer (0.5 mol/L, pH 7.2) containing 0.1 mmol/L dithiothreitol, centrifuged at 
40,000 x g for 30 min, and stored at --70 °C until analysis. The assay mixture contained 1.0 
.mol/L potassium phosphate (pH 6.7), 0.5 mol/L sodium ascorbate, 0,1 mol/L EDTA, 10 
mmol/L menadione, 1.0 mmol/L FAD, and 25 mmol/L 5 -t 14CH3] -THF (74 Bq/µmol). The 
reaction was initiated with the protein supernatant and incubated for 3 0 min at 3 0 °C . The 
reaction was terminated with dimedone (3 g/L in 1 mol/L sodium acetate) and samples were 
placed in a boiling water bath for 5 min. After being placed on ice, a 1.0 mL aliquot was 
extracted with toluene and a 1.0 mL aliquot of the resulting supernatant (500 x g for 5 min) 
was subjected to liquid scintillation counting. 
MS determination. 
The activity of MS was determined as previously described (23). Briefly, liver 
supernatant samples were incubated at 37 °C for 1 h in a reaction mixture containing sodium 
phosphate buffer (500 mmol/L, pH 7.5), cyanocobalamin (1.3 µmol/L), dithiothreitol (1 
mol/L), SAM (10 mmol/L), 2-mercaptoethanol (82.4 mmol/L), homocysteine (100 mmol/L), 
and 15 mmol/L 5-(14CH3]-THF (6.44 kBq/µmol). Reactions were stopped with the addition 
of ice-cold water and samples were immediately applied to AG 1-X8 (Cl form) resin columns 
(Bio-Rad, Hercules, CA). Flow through fractions (3 mL total) were collected and subjected 
to liquid scintillation counting. 
Amino acid analysis. 
Amino acids from plasma samples were prepared by using a EZ:faastTM GC-MS 
analysis kit (Phenomenex, Torrance, CA). Derivatized samples were analyzed by gas 
chromatography-mass spectrometry (Agilient Technologies, 6890/5973). 
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Statistical analysis. 
The mean values of each treatment group were subjected to a one-way ANOVA (24). 
If the ANOVA was significant (P < 0.05), the means were compared using Fisher's least 
significant difference procedure. 
Results 
ATRA induced hepatic GNMT in adose-dependent manner. 
Hepatic GNMT activity (Figure 2.2A) and abundance (Figure 2.ZB) increased in 
response to graded levels of ATRA. For the 10-d treatment period, 5 µmol/kg BW was the 
lowest dose of ATRA that significantly increased (105%) GNMT activity. GNMT activity 
continued to increase with respect to the dose of ATRA administered, achieving a maximal 
response (231%) at 30 µmollkg BW. Immunoblotting analysis indicated that the changes in 
activity were also reflected in GNMT protein abundance. 
Hepatic GNMT was rapidly induced by administration of ATRA. 
GNMT activity was significantly increased 31 and b2% following a single dose of 
ATRA (30 µmol/kg BW) compared to either group of untreated rats (d 0 and 8, respectively) 
(Figure 2.3A) . Maximal .induction was achieved on d 4 and 8, exhibiting a 95 and 8 3 
increase, respectively, compared to control values on d 0. Hepatic GNMT protein abundance 
also increased as a function of treatment time with ATRA, (Figure 2.3B). 
Plasma homocysteine and methionine concentrations were significantly decreased by 
ATRA treatment. 
ATRA treatment resulted in a 5 3 %decrease in plasma homocysteine levels (Figure 
2.4). Similarly, plasma methionine concentrations were decreased 42% from 50.3 to 29.1 
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FIGURE 2.2 Dose-dependent induction of hepatic glycine N-methyltransferase (GNMT) by 
all-trans-retinoic acid (ATRA). Data are means ± SEM, n=6. Bars without common letter 
denote significance (P < 0.05). Panel A, GNMT activity as a function of graded doses of 
ATRA given for 10 d. Panel B, representative immunoblot of GNMT protein abundance 
following 10-d treatment with various doses of ATR.A. 
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FIGURE 2.3 Time-course induction of hepatic glycine N-methyltransferase (GNMT) by all-
trans-retinoic acid (ATRA) treatment. Data are means f SEM, n = 6. Asterisks denote 
values that were significantly different from control values; (*P < 0.05, * * P < 0.01). Panel 
A, GNMT activity as a function of treatment time with ATRA (30 µmol/kg BW). Open and 
closed circles represent mean values from control (vehicle-treated) and ATRA-treated rats, 
respectively. Panel B, representative immunoblot of GNMT protein abundance for each 
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FIGURE 2.4 All-trans-retinoic acid (ATRA) reduces the circulating concentrations of 
methionine and homocysteine. Following 10-d ATRA (30 l.tmol/kg BW) treatment, plasma 
samples were analyzed for amino acid concentrations. Data are means ~ SEM, n = 6. Bars 
with an asterisk denote significance from control values (*P < 0.05). 
Hepatic folate coenzyme concentrations and activity of MTHFR were not affected, 
whereas MS activity was increased by ATRA administration. 
The hepatic concentrations of THE and 5-methyl-THF were not affected by 
administration of ATRA (30 µmol/kg BW for 10 d) (Table 2.1). Likewise, the hepatic 
activity of MTHFR was not significantly altered following treatment with ATRA. In 
contrast, the hepatic activity of the homocysteine remethylation enzyme MS was elevated 
40% in ATRA-treated rats compared to control activity values. 
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Table 2.1 Effect of all-trans-retinoic acid (ATRA~) 
on folate coenzymes and enzymes 






nmol/g l fiver 
1.74 ± 0.2 02 1.8 5 ± 0.44 
1.67±0.28 2.22±0.46 
nmol/(min • mg protein) 
226 ± 44 357 ± 85 
31.8±3.0 45.5±2.4* 
l Abbreviations: ATRA, all-trans-retinoic acid; MS, methionine synthase; MTHFR, 
5,10-methylenetetrahydrofolate reductase; THF, tetrahydrofolate. 
2Data are means ~ SEM, n = 6. Value with asterisk is significantly different from 
control value (* P < 0.05). 
Discussion 
The availability of methyl groups for SAM-dependent transmethylation reactions is 
important in the production of vital biological compounds. Thus, regulation of folate and 
methyl group metabolism is critical to ensure optimal health, because disruption of these 
interrelated pathways is associated with a number of detrimental conditions (4,25,26). We 
have shown here and in our previous studies that the administration of retinoid compounds in 
large doses for 7-10 d induced GNMT, thereby compromising the methylation of important 
biological compounds. Of particular significance in this study was the observation that the 
ability of ATRA to modulate GNMT and methyl group metabolism was rapid (i.e., a single 
dose), and could be demonstrated at a much lower level (5 µmol/kg BW). These findings 
have tremendous relevance for humans that use retinoids such as ATRA (tretinoin, 
Vesanoid°  or 13-cis-retinoic acid (isotretinoin, Accutane° ) in the treatment of certain 
cancers and skin disorders. Recommended dosages for both of these retinoid compounds 
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typically range from 2-7 µmol/ kg BW and are administered for a period of 15-20 wk (27). 
Although we have found that 5 µmol/kg BW was the minimum effective dose in a 10-d 
study, we would expect that even lower levels of retinoid compounds would be effective at 
perturbing GNMT and methyl group metabolism when administered for a longer time period. 
Taken together with our previous demonstration (14) that retinyl palmitate induced GNMT, 
although to a lesser extent than ATRA or 13-cis-retinoic acid, the unsupervised use of 
vitamin A supplements for a sufficient period of time may have adverse effects on methyl 
group metabolism as well. We are currently in the early stages of conducting research 
focused on the effect of chronic retinoid administration. 
We have extended our previous work by examining the potential alterations expected 
in homocysteine metabolism as a result of retinoid administration. The concentration of 
homocysteine can be modulated by changes in its production (i.e., via transmethylation) and 
metabolism by either the transsulfuration pathway or remethylation by folate-dependent 
and/or folate-independent mechanisms (28). For plasma homocysteine levels, renal 
homocysteine metabolism plays a significant role as well. In our studies, the marked 
induction of GNMT would be expected to result in the accumulation of homocysteine, 
particularly if the capacity of the transsulfuration and/or remethylation pathways were 
compromised. However, we -found that ATRA administration reduced circulating 
homocysteine levels, indicating that the metabolism of homocysteine may be enhanced. 
Likewise, we have reported in an earlier study that ATRA was effective at reducing elevated 
homocysteine concentrations to normal levels in adrenalectomized rats; however, the 
reduction of plasma homocysteine concentrations by ATR.A in intact animals did not reach 
statistical significance (16). This discrepancy may reflect the difference in the experimental 
design, as the earlier study was only for 5 d and utilized older rats. We have found in a 
number of studies that older rats exhibit increased sensitivity to retinoids, as indicated by 
further increases in GNMT activity, but are less sensitive to the effect of retinoids on 
homocysteine metabolism 1 . 
1 Knoblock, V.E. & Schalinske, K.L., unpublished data. 
42 
In an attempt to begin to address how retinoid administration modulates 
homocysteine metabolism, we examined the hepatic folate-dependent remethylation of 
homocysteine as a passible mechanism. Although the hepatic concentration of 5-methyl-
THF and the activity of MTHFR were not statistically altered, the elevated activity of MS 
clearly indicates that remethylation of homocysteine by the one-carbon pool was enhanced in 
ATRA-treated rats. Thus, it appears that the folate-dependent one-carbon pool attempts to 
compensate for the retinoid-mediated loss of methyl groups by increasing their supply. 
Additional in vivo regulation may contribute to homocysteine remethylation as well. For 
example, allosteric factors such as the concentration of SAM plays a significant role in the 
regulation of MTHFR by inhibiting its enzymatic activity (5,6). We have found that 
retinoids reduce hepatic SAM concentrations (29, 0); thus, an elevation in the endogenous 
MTHFR would be expected to further contribute to homocysteine remethylation. 
Similar to homocysteine, it appears that ATRA treatment increased the catabolism of 
methionine, as indicated by the reduction in circulating methionine levels. This observation 
supports our earlier work and others that retinoid compounds have the ability to enhance 
methionine catabolism under both normal and excess dietary .methionine conditions (29-32). 
This finding also underscores the implication that the effect of retinoids on hepatic sulfur 
amino acid metabolism may have an impact on reducing their availability for other tissues/ 
cells. 
It is not clear how retinoid administration may alter the metabolism of homocysteine 
in humans. Schulpis et al. (33) reported an inability to catabolize a methionine load and 
increased homocysteine levels in adults that received 0.5 mg/kg BW (i.e., 1.7 µmol/kg BW) 
isotretinoin (13-cis-retinoic acid) for 45 d; however, this may reflect the hepatotoxicity 
associated with long-term isotretinoin usage exhibited by these patients. In our rat studies 
using large (30 µmol/kg BW) doses of ATRA administered for 10 d, serum liver enzymes 
were not elevated (data not shown). It will be important in firture research to determine the 
potential impact of these findings on humans. Extrapolation of rat studies focused on factors 
that modulate homocysteine metabolism to the human situation has met with conflicting 
results. For example, the alterations seen in homocysteine metabolism as a function of 
diabetes appears to be similar to that observed in humans (34), whereas thyroid status has 
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opposing effects on homocysteine metabolism when comparing the findings from rat studies 
to those reported from human research (3 5). 
In summary, we have shown that the administration of ATRA, in doses equivalent to 
those used cynically, was effective at altering hepatic GNMT activity and potentially 
perturbing methyl group metabolism. Moreover, this effect was rapid and resulted in 
increased metabolism of methionine and homocysteine, the latter due, at least in part, to 
enhanced folate-dependent remethylation. These findings may have a significant impact on a 
number of individuals that may be exposed to retinoid usage. It has recently been reported 
that the use of isotretinoin has increased 2.5-fold in the last 8 years, averaging 800,000 new 
prescriptions per year (36). Moreover, it would be anticipated that a significant percentage of 
these individuals may have suboptimal nutritional status, polymorphisms of key enzymes, or 
a physiological condition that further compromises folate function and methyl group 
metabolism. We have recently shown that the combination of glucocorticoid treatment/ 
diabetes and retinoid administration exerts an additive effect on disrupting methyl group 
metabolism (16). 
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CHAPTER 3. GENERAL CONCLUSIONS 
Summary 
The role of the folate-dependent one-carbon pool and methyl group metabolism is 
important in health and disruptions to the interrelated cycles are implicated in the 
development of cardiovascular disease, cancer, and neural tube defects. Folate is needed for 
normal cellular function and perturbation from genetic enzyme polymorphisms, nutritional 
deficiencies, drug therapies or hormonal fluctuations can affect health, whether it is in the 
form of cardiovascular disease from excess homocysteine concentration, or the disruption of 
DNA synthesis leading to tumor formation. 
One such perturbation to methyl group metabolism has come in the form of synthetic 
retinoids that are administered in the field of dermatology and the treatment of cancer. These 
vitamin A derivatives are useful but may come at the expense of folate and methyl group 
metabolism. Current research in this area is trying to elucidate the connection between 
vitamin A and methyl group metabolism and ultimately, the consequences involved in the 
administration of these synthetic retinoids as well as the dietary intake of retinoids in high 
doses. 
The studies described in Chapter 2 demonstrate the ability of all-trans-retinoic acid 
(ATRA) on methionine metabolism. ATR.A administered in doses similar to those seen in 
clinical dermatology and for a shorter time increased the enzyme activity of glycine N-
methyltransferase (GNMT) and protein abundance and decreased plasma homocysteine and 
methionine concentrations, the result of enhanced homocysteine metabolism. The increased 
GNMT activity decreased the S-adenosylmethionine-dependent creative production that was 
reflected by a decrease in urinary creatinine (Appendix A). Transsulfuration metabolites 
from homocysteine were also affected and this was demonstrated by a decrease in both 
urinary inorganic sulfates and plasma glutathione. 
Our lab has shown that in addition to ATRA, other factors affect GNMT activity, 
leading to disruption of methyl group metabolism. Areas we have studied include dietary 
protein levels, glucocorticoid treatment, age and gender influence, and altered thyroid 
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function. Alterations in folate-dependent one-carbon and methyl group metabolism are 
driving our research with a goal of determining how modulation of these pathways affects 
overall health. One must be cautious when extrapolating this data from rats to humans but 
this research can give scientists valuable insight on disorders where these pathways are 
involved. 
Recommendations for Future Research 
Understanding the folate-dependent one-carbon pool and methyl group metabolism 
has taken a new turn as science has evolved with molecular techniques. Gene sequencing 
and DNA techniques aid in determining the characteristics of the enzymes and cofactors 
involved in these important pathways. The involvement of methyl group metabolism in 
diabetes has only recently been determined and the next 10 years of research in this area may 
assist in elucidating the etiology of this debilitating disease. The strong correlation of 
homocysteine and folate to cardiovascular disease has launched a multitude of studies 
looking at preventive lifestyle factors as well as the genetic influence that can cause this life-
threatening disease. Identifying plasma homocysteine levels as a marker may help in the 
prevention of cardiovascular disease and aid researchers with other diseases in which 
coenzymes of methyl group metabolism may be involved. 
In regards to the application of retinoids in the clinical setting, further research could 
be applied to examine the metabolites within methyl group metabolism as well as enzymes 
and coenzymes of rats treated with ATRA at low concentrations for a time frame (4-5 
months) similar to the clinical dosing regime. This would clarify the intermediate effect 
ATRA has on methyl group metabolism in humans are undergoing retinoid therapy. Using 
the same study design but continuing the life span of the rat to detect tumor formation would 
clarify if there were a carcinogenic effect from the DNA hypomethylation that occurs with 
ATR.A administration. Another step to take in researching retinoid therapy would be a 
clinical study to correlate the animal data to human application. Patients undergoing 
retinoid therapy could have blood samples tai{en for the analysis of red blood cell folate 
levels, lymphocyte DNA, and plasma homocysteine and methionine would help scientists 
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understand the relationship between retinoids and the folate-dependent one-carbon pool and 
methyl group metabolism. 
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APPENDIX A. TRANSMETHYLATION AND TRANSSULFURATION 
PRODUCTS AFFECTED BY ALL-TRANS-RETINOIC ACID 
TREATMENT IN RATS 
Introduction 
The creatine-creatine phosphate system plays an important role in storing energy and 
the transmission of energy when needed. According to Stocker-Ipsiroglu (1), creatine is only 
produced in the liver and pancreas and transported to the brain and muscles where it is 
utilized by creatine kinase and ATP/ADP. Guanidinoacetate is the precursor of creatine and 
is methylated via the enzyme guanidinoacetate methyltransferase and consumes ~75% of the 
S-adenosylmethionine (SAM)-dependent methylation reactions in the liver. After utilization 
of this energy source, creatine is nonenzymatically cycled to creatinine and is excreted in the 
urine. Daily excretion of creatinine is directly proportional to total body creatine and can be 
helpful in diagnosis of creatine-deficient states. 
Another metabolite measured in the urine is inorganic sulfate, which is an end 
product of the transsulfuration pathway. Homocysteine is irreversibly converted to 
cystathionine, which is further catabolized to ammonium, a-ketobutyrate, and cysteine. 
cysteine can be involved in the production of glutathione. Stipanuk et al. (2) showed that 
low cysteine availability increased the utilization of glutathione, avoiding decreased levels. 
High cysteine levels favor the utilization of sulfate and taurine, removing the cell of excess 
cysteine. These sulfated products are excreted in the urine when no longer biologically 
needed. Plasma glutathione was measured as well as inorganic sulfates to determine if 
homocysteine catabolism induced by elevated activity of glycine N-methyltransferase 
(GNMT) altered these transsulfuration products. 
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Materials and Methods 
Animals and diet. 
This study's design involving the use and care of animals is the same one in Chapter 
2 and is described in detail on pp. 32-33. In regards to the samples taken for analysis in this 
appendix, rats were anesthetized at the end of the treatment period and whole blood was 
obtained via cardiac puncture for the determination of plasma glutathione and creatinine. 
Rats from the 0 and 3 0 µmol/kg B W all-Mans-retinoic acid (ATRA) groups were placed in 
metabolic cages 24 hours before they were killed to collect urine for the analysis of urinary 
inorganic sulfates and creatinine. 
creatinine determination. 
Urinary creatinine concentrations were measured spectrophotometrically using a 
commercial kit (Sigma, St. Louis, MO) with slight alterations. Using urine from the same 
pool as the inorganic sulfate assay, 3.0 mL alkaline picrate solution (50 mL creatinine color 
reagent and 10 mL 1.0 N sodium hydroxide) was added to 100 µL of urine. After being 
vortexed, an aliquot of 2.0 mL of the mixture was transferred to a cuvette and read at 500 
nm. After an 8 min incubation period, 60.6 ~.iL acid reagent was added, vortexed and read 
after another incubation period of 5 min. Samples were analyzed by taking the difference 
between the two measurements and using the standard curve previously generated. Assay 
was performed on 0 and 3 0 µmol kg/B W ATRA. 
Inorganic sulfate determination. 
Urine levels from 0 and 30 µmol/kg BW ATRA were brought up to a total volume of 
22 mL and stored at —20 °C until analysis. A 50 µL aliquot was used to determine inorganic 
sulfate levels according to the method of Lundquist et al. (3). A solution consisting of 1.0 
mL HCl (0.5 mol/L) and 1.0 mL stabilizing agent [9.77 g barium chloride (0.04 mol/L), 150 
g polyethylene glycol 8000, and 200 µL sodium sulfate (50 mmol/L) into 1.0 L water] was 




Plasma glutathione concentrations were determined according to the method of 
Ubbink et al. (4). In brief, heparinized blood from the cardiac puncture was immediately 
centrifuged (3 $00 x g for 6 min) and plasma samples were stored at —70 °C until 
derivatization. For derivatization, N-acetylcysteine (1 mmol/L) was added as an internal 
standard to 300 µL of plasma and 10% tributlyphosphine in dimethylformamide solution was 
added followed by incubation at 4 °C for 3 0 min. The reaction was stopped with 10% 
trichloroacetic acid-1.0 mmol/L EDTA and following centrifugation at 1000x g for 5 min, 
the supernatant was added to a solution containing borate buffer (0.125 mol/L, pH 9.5), 
sodium hydroxide (1.5 5 mol/L), and 4-fluoro-7-sulfobenzofurazan (1 mg/mL). Filtered 
samples were analyzed by HPLC using fluorometric detection and a mobile phase consisting 
of 96% potassium monophosphate (0.1 mol/L, pH 2.1) buffer and 4% acetonitrile. 
Statistical analysis. 
The mean values of each treatment group were subjected to a one-way ANOVA (5). 
If the ANOVA was significant (P < 0.05), the means were compared using Fisher's least 
significant difference procedure. T-test was used in the analysis of plasma glutathione 
values. 
Results 
Transsulfuration metabolites were decreased by ATRA administration. 
The transsulfuration metabolites glutathione and inorganic sulfates were affected by 
ATRA administration (30 µmol/kg BW for 10 d) (Table A.1). Plasma glutathione was 
significantly lower (P = 0.022) in rats treated with ATRA. Urinary inorganic sulfate levels 
were 21 %lower in rats treated with ATRA compared to control rats that were treated with 
vehicle, corn oil. 
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Plasma creatinine concentrations were not affected whereas urinary creatinine 
concentrations were lower in ATRA-treated rats. 
There was no difference in plasma creatinine in control versus rats treated with 
ATRA. The administration of ATRA to rats caused a 30% decrease in urinary creatinine 
(0.39 mg/24 h) compared to the control group( 0.56 mg/24 h) (Table A.l). 
Table A.1 Transsulfuration and 
transm ethylation metabolites 
ATRA 1 (µmol/kg BW) 
Metabolite 0 30 
Glutathione (µmol/L plasma) 21.5 t 2.1 153 t 0.8"` 
Urinary Sulfates (µmol/24h) 0.38 f 0.03 0.30 t 0.02' 
Urinary Creatinine (m~24h) 0.56 t 0.05 0.39 t 0.04' 
Creatinine (µmol/L plasma) 81.9 t 8.9 77.9 t 7.5 
1 Abbreviations : all-tans-retinoic acid, ATRA. 
2 Data are means ± SEM, n=6; #represent significance in ~-test using 0 and 30 ATR.A 
(µmol/kg BW) groups (P < 0.05); *represents significance in ANOVA (P < 0.05). 
Discussion 
The impact of ATRA on methyl group metabolism has been demonstrated in Chapter 
2; however, the subsequent decrease in metabolites from this pathway was not shown. The 
administration of ATRA in a pharmacological dose (30 µmol/lcg BW) for 10 days had a 
profound effect on products that arise from the SAM-dependent transmethylation reaction 
and the catabolism of homocysteine. Creatine is an important carrier of energy and is 
primarily produced in the liver. Its catabolism produces creatinine, which is then excreted 
from the body. This can provide researchers with a valuable test to measure creatine stores. 
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There are numerous methyltransferases available to utilize the methyl group SAM releases to 
produce important biological products. Another methyltransferase, glycine N-
methyltransferase (GNMT) is present for a regulatory need of maintaining the 
transmethylation potential. The administration of ATRA is known to induce GNMT activity 
and cause DNA hypomethylation, another product formed from the transmethylation reaction 
(6,7). The increase in GNMT activity appears to prevent other methyltransferases from 
methylating more important biological products (i.e., DNA, creatine). 
Additionally, homocysteine metabolism was perturbed by ATRA administration. 
Chapter 2 showed the decrease in plasma homocysteine and this is reflected in the decrease 
in plasma glutathione. Another end-product from homocysteine catabolism is inorganic 
sulfate and was also decreased in the urine after the administration of ATRA. These results, 
along with those conveyed in Chapter 2, can be examined together in the analysis of ATRA's 
impact and what the overall health consequences may be to those who use retinoids in high 
doses clinically or in a supplementation. 
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APPENDIX B. INCREASED PROTEIN INTAKE INDUCES GLYCINE 
N-METHYLTR.ANSFERASE ACTIVITY IN RATS TREATED WITH 
ALL-TRANS-RETINOIC ACID 
Introduction 
Methionine is an integral part of methyl group metabolism and the pathway is often 
referred to as methionine metabolism. Methionine favors conversion to S-
adenosylmethionine (SAM), an activated molecule that can regulate enzyme activity 
concurrent to its concentration (1). The enzymes methionine synthase (MS) and 
betaine:homocysteine methyltransferase (BHMT) respond to fluctuations in methionine 
concentration, as shown in Table l . l (2). A deficiency of methionine is handled efficiently 
as inducing enzyme activity within the methionine pathway, resulting from decreased SAM 
concentration by increasing activity and remethylating homocysteine (3). If the methionine 
concentration increases beyond the metabolic needs of SAM, the transsuifuration pathway 
lowers the methionine level via the enzyme cystathionine ~-synthase (CBS) to irreversibly 
catabolsz homocysteine (4,5). Finkelstein et al. (1) reported that when a high .protein diet is 
ingested followed by a low protein diet, the conversion of homocysteine to cystathionine, the 
first product in the transsulfuration pathway drops from 70% to 10%. The same phenomenon 
occurs when high doses of SAM and S-adenosylhomocysteine (SAH) are given, causing 
homocysteine catabolism to cystathionine to increase from 39% to 82%. Another enzyme 
that is affected by an increase in protein intalte is glycine N-methyltransferase (GNMT), 
which is viewed as a regulatory enzyme that is active in times of excess SAM levels. GNMT 
catalyzes the donation of the SAM methyl group to glycine to produce sarcosine, a molecule 
with no known biological function (6). Ingestion of a 3% methionine diet results in an 
increase in hepatic GNMT activity to rid the cell of excess methyl groups available from 
increased SAM concentration (7). 
Because of its overall impact on the body, the homeostasis of methyl group 
metabolism is important to study to determine what occurs when outside factors are added. 
Identifying the disturbances that take place when retinoids are administered has been 
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established. It is important to test the outcome that additional factors have on the pathway. 
The following results show the alterations of a 20% casein diet along with the administration 
of either vehicle (corn oil) or 30 µmol all-t~c~ns-retinoic acid (ATR.A)/kg Bw in the rat 
model. These treatment groups were compared to control groups fed a diet consisting of 
10% casein, a level of protein needed for basal metabolism, combined with the 
administration of ATRA. or the vehicle. 
Materials and Methods 
Chemicals and reagents. 
Reagents were obtained from the following: S-adenosyl-L-[methyl-3H]methionine, 
New England Nuclear (Boston, MA); phenylmethylsulfonyl fluoride and ATRA, Calbiochem 
(La Jolla, CA); and S-adenosyl-L-methionine, Sigma Chemical (St. Louis, MO). 
Animals and diet. 
All animal experiments were approved by and conducted in accordance with Iowa 
State University Laboratory Animal Resources Guidelines. For all studies, male Sprague-
Dawley (Harlan Sprague-Dawley, Indianapolis, IN) rats (50-74 g) were housed in plastic 
cages in a room with a 12-h light: dark cycle. Rats were acclimated to the control diet 
containing- 10% methionine from casein (8) with the exception of vitamin/mineral mix 93 for 
7 d and the oral administration of corn oil for 6 d. Half of the rats were fed a 20% methionine 
diet by increasing the casein concentration in the diet. ATRA was administered to the 
treatment group as 30 ~.imol/kg Bw using corn oil as the vehicle for a total of 8 d. At the end 
of the treatment period, rats were anesthetized and whole blood was obtained via cardiac 
puncture for determination of plasma homocysteine concentrations. Liver samples were 
obtained for determining the enzymatic activity of GNMT and folate coenzyme 
concentrations, as well as lipid and triglyceride content. 
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Measurement of GNMT activity. 
GNMT enzymatic activity was assayed as described by Cook and Wagner (6) with 
minor modifications. Portions of liver were homogenized in three volumes of ice-cold 
phosphate buffered (10 mmol/L, pH 7.0) sucrose (0.25 mol/L) containing 1 mmol/L EDTA, 
1 mmol/L sodium azide, and 0.1 mmol/L phenylmethylsulfonylflouride. After centrifugation 
(20,000 x g for 30 min), supernatants were stored with 2-mercaptoethanol (10 mmol/L) at —
70° C. The assay contained 1 mmol/L Tris buffer (pH 9.0), 5 mmol/L dithiothreitol, 10 
mmol/L glycine, and 1 mmol/L S-adenosyl-L-[methyl-3H]methionine (47.7 kBq/µmol) and 
the reaction was initiated with 250 µg of the protein supernatant. For the determination of 
total soluble protein in the tissue extract, a commercial kit (Coomassie Plus, Pierce, 
Rockford, IL) based on the method of Bradford (9) was used with bovine serum albumin as a 
standard. 
Lipid detection. 
Lipids were analyzed according to Folch et al. (10). 1.0 g of liver tissue was 
extracted and wrapped in aluminum foil and stored at -70 °C until analysis. After warming 
to room temp, liver samples were weighed, added to 10.0 mL ice-cold 2:1 
chloroform/methanol, and homogenized. Homogenate was then applied to a moistened 
Whatman filter placed in a funnel/graduated cylinder apparatus to be filtered. Additional 
chloroform/methanol solution was added to the sample to reach 20 mL. The funnels were 
removed and 4.0 mL calcium chloride (0.05%) was added. Enclosed graduated cylinders 
were inverted 5 times and allowed to set overnight. Extraction occurred and the upper phase 
was pipetted off carefully as to not disrupt the interface. 1.0 mL of upper phase solvent 
(8:4:3 containing chloroform: methanol: 0.04% calcium chloride) was added and gently 
mixed by rotation before the top phase was pipetted off. This procedure was performed 2 
more times and 5 drops of methanol were applied afterwards to remove the interface. The 
chloroform/methanol mixture was added to bring the solution up to 20 mL and gently mixed. 
Three aluminum cups per sample were preweighed and 5.0 mL of solution were added to 
each. Solution was allowed to evaporate overnight and aluminum cup was weighed to 
measure precipitate. Difference between initial cup weights and the precipitate represented 
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1/4 of total lipids/g liver. Leftover solution was stored at room temp for the analysis of 
triglycerides. 
Triglyceride detection. 
Triglycerides were measured spectrophotometrically using a commercial kit (Sigma, 
St. Louis, MO). Briefly, 100 µL solution from the lipid assay, was added to a test tube and 
the solvent was evaporated in a vacuum state. The reagents the kit provided were added, 
tubes were vortexed, and incubated for 10 min at 30 ° C. The solution was transferred to a 
cuvette and read at 540 nm. The absorbance was analyzed using the standard curve 
generated earlier and divided by the initial liver weight from the lipid assay to find mg 
triglyceride/g liver. 
Statistical analysis. 
The mean values of each treatment group were subjected to a two-way ANOVA (11). 
If the ANOVA was significant (P < 0.05), t11e means were compared using Fisher's least 
significant difference procedure and analyzed by one-way ANOVA to identify significance 
within groups. 
Results 
ATRA induced hepatic GNMT and was exacerbated by the 20% casein diet. 
GNMT activity was significantly higher in rats treated with ATR.A as shown in 
Figure B.1. The application of the 20% casein diet plus ATRA (30 µmol/kg BW) amplified 
GNMT activity 36% compared to control diet treated with ATRA. The GNMT activity of the 
20% casein diet ATRA-treated group was 184% higher compared to the group fed the 20% 
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Figure B.1 Induction of GNMT in rats treated with ATRA and. or 20% casein diet. Data are 
means ± SEM, n = 5. Bars with asterisks differ, (* P < 0.0~, ** P < 0.01). 
20% casein diet had a protective effect from increased hepatic lipid and triglyceride 
levels in rats treated with ATRA compared to ATRA-treated rats on the control diet. 
Rats treated with ATRA (30 µmol/kg BW) experienced significantly higher hepatic 
lipids than control group (Figure B.2). This effect was not seen in ATRA-treated rats that 
consumed the 20% casein diet. The ATRA-treated group on the control diet had 230% 















  Lipids 
10% caseii~/0 10% casein/30 
T
20% casein/0 20% casein/30 
Diet/ATRA (~.u»oVkg BVV} 
Figure B.2 The effect of ATRA and 20% casein diet on rats. ATRA increased liver 
lipids and triglycerides on rats fed the 10% casein diet but did not affect those on the 20% 
casein diet. a denotes significance compared to all other groups. b denotes significance 
compared only the 20% casein diet. Data are means ± SEM, n = 5. Bars with asterisks 
differ, (* P < 0.05). 
Discussion 
GNMT is an important regulatory enzyme in methyl group metabolism. We have 
shown that the application of ATR.A (30 µmol/kg BW) to rats induces its activity and 
abundance while ingesting a control diet (10% casein) (12,13). When the protein amount in 
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the diet increases (20% casein), there appears to be an additive effect with ATRA on GNMT 
activity. The increase in protein correlates to an increase in overall methionine, which 
corresponds to increased cellular methionine concentration within methyl group metabolism. 
The increased amount of methionine may have led to higher SAM concentration and a need 
for GNMT to dispose of excess methyl groups. The control diet includes 10% casein and 
added methionine to produce a total methionine content of 0.58%; additionally, the 20% 
casein diet used in this study has a total methionine content of 0.86%. Rowling et cal. (14) 
found an increase in GNMT activity from a 1.0% methionine diet while the 0.5 %methionine 
diet did not affect the activity. 
The two diets used in this study did not alter GNMT activity when ATRA was not 
administered (vehicle corn oil was given). However, GNMT activity from the 20% 
casein/ATR.A treatment group was 3 6% higher than the group receiving the 10% 
caseinlATRA. These results indicate the additive effect of two perturbations to methyl group 
metabolism and the subsequent increase in GNMT activity. 
The addition of increased methionine in the diet appears to protect the liver from 
ATRA-mediated triglyceride and hepatic lipid increases. Liver lipids were lowered in 
ATRA-treated rats fed the 20% casein diet compared to those treated with ATR.A on the 
control diet. Triglyceride levels of ATR.A-treated rats fed the control diet were significantly 
higher than rats fed the 20% casein diet. The impact of increased protein intal{e on methyl 
group metabolism is important to document. In cases of genetic polymorphisms of enzymes 
and other nutritional deficiencies, increased protein may have a detrimental effect in the 
methionine metabolism. However, it does have a protective effect against fatty liver, which 
is a side effect of ATRA administration (15) and is important in the area of hepatic cancer. 
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